VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYNB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYNBKyntra Bio, Inc.
$2.04$15M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKYNBFinancials

Kyntra Bio, Inc. (KYNB) Income Statement

14Y historyFree accessUpdated daily

Revenue has been highly erratic, falling from $46.3M in 2024Q3 to $1.8M in 2026Q3, while operating margin stayed negative at -7.3% in the latest quarter and gross margin ranged from -31.6% to 136.3%, suggesting margins are unanchored by a stable revenue base.

Income StatementBalance SheetCash FlowRatios

KYNB Income Statement

Annual statement

KYNB Income Statement

Kyntra Bio, Inc. (KYNB) annual income statement — 14-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Sales/Revenue5.3M6.44M29.62M46.8M140.73M235.31M176.32M256.58M212.96M125.67M179.58M180.83M137.6M102.17M65.93M
Revenue Growth %104.49%-78.26%-36.71%-66.74%-40.19%33.46%-31.28%20.48%69.46%-30.02%-31.41%34.68%54.96%-
Cost of Goods Sold3.65M556K15.56M3.96M20.28M449.19M8.87M1.15M235.84M196.52M187.21M214.09M150.79M85.71M74.22M
COGS % of Revenue-8.63%52.53%8.47%14.41%190.89%5.03%0.45%110.74%156.38%104.25%118.39%109.59%83.89%112.57%
Gross Profit-104K5.88M14.06M42.84M120.45M-213.88M167.45M255.43M-22.88M-70.85M-7.63M-33.26M-13.19M16.46M-8.29M
Gross Margin %-1.96%91.37%47.47%91.53%85.59%-90.89%94.97%99.55%-10.74%-56.38%-4.25%-18.39%-9.59%16.11%-12.57%
Gross Profit Growth %--58.15%-67.18%-64.43%156.32%-227.73%-34.44%1216.34%67.7%-828.68%--152.11%-180.15%298.58%-
Operating Expenses59.38M51.78M164.48M365.56M421.48M74.65M359.33M344.74M299.65M248.28M233.23M258.45M187.7M110.12M93.16M
OpEx % of Revenue-804.02%555.27%781.07%299.49%31.72%203.8%134.36%140.71%197.57%129.88%142.93%136.41%107.78%141.29%
Selling, General & Admin28.88M27.71M49.33M86.48M124.69M109.12M106.41M135.48M63.81M51.76M46.02M44.36M36.91M24.41M18.93M
SG&A % of Revenue-430.26%166.54%184.78%88.6%46.37%60.35%52.8%29.96%41.19%25.63%24.53%26.82%23.89%28.72%
Research & Development29.92M23.52M95.69M266.47M296.79M387.04M252.92M209.26M235.84M196.52M187.21M214.09M150.79M85.71M74.22M
R&D % of Revenue-365.17%323.05%569.35%210.89%164.48%143.45%81.56%110.74%156.38%104.25%118.39%109.59%83.89%112.57%
Other Operating Expenses586K553K19.45M12.61M0-421.51M0042.16M00016K156K181K
Operating Income-58.33M-45.9M-150.42M-322.72M-301.02M-288.53M-191.88M-89.31M-86.69M-122.61M-53.65M-77.63M-50.1M-7.95M-27.22M
Operating Margin %-1099.92%-712.66%-507.8%-689.53%-213.9%-122.62%-108.83%-34.81%-40.71%-97.57%-29.88%-42.93%-36.41%-7.78%-41.29%
Operating Income Growth %-69.49%53.39%-7.21%-4.33%-50.37%-114.84%-3.02%29.29%-128.52%--54.93%-530.29%70.8%-
EBITDA-58.31M-45.15M-147.72M-312.79M-290.42M-273.72M-169.83M-67.86M-80.13M-116.51M-47.61M-71.95M-45.63M-2.87M-21.63M
EBITDA Margin %-1099.53%-701.04%-498.71%-668.31%-206.36%-116.32%-96.32%-26.45%-37.63%-92.71%-26.51%-39.79%-33.16%-2.8%-32.8%
EBITDA Growth %52.36%69.44%52.77%-7.7%-6.1%-61.17%-150.27%15.31%31.22%-144.7%--57.67%-1492.74%86.75%-
D&A (Non-Cash Add-back)21K748K2.69M9.93M10.6M14.81M22.05M21.45M6.56M6.1M6.04M5.68M4.47M5.08M5.6M
EBIT-83.15M-58.29M-145.12M-315.13M-293.43M-348.53M-186.33M-73.77M-75.13M-110.85M-51.03M-74.5M-48.4M-4.24M-22.64M
Net Interest Income-3.15M-5.82M-2.95M-501K6.16M-1.07M3.15M12.67M577K-3.27M-8.1M-7.91M-9.4M-6.99M-5.63M
Interest Income4.06M2.94M5.3M7.59M7.6M05.55M15.55M11.57M6.43M2.63M3.12M1.69M3.71M4.4M
Interest Expense5.57M8.76M8.25M8.1M1.44M1.07M2.4M2.88M10.99M9.71M10.72M11.03M11.11M10.7M10.03M
Other Income/Expense40.72M-12.4M-2.95M-501K7.73M-1.15M2.95M12.67M577K-3.27M-8.1M-7.91M-9.4M-6.99M-5.45M
Pretax Income-17.61M-58.29M-153.37M-323.22M-293.3M-289.68M-188.93M-76.64M-86.12M-125.88M-61.75M-85.54M-59.5M-14.94M-32.67M
Pretax Margin %-332.1%-905.19%-517.76%-690.6%-208.4%-123.1%-107.15%-29.87%-40.44%-100.17%-34.39%-47.3%-43.24%-14.63%-49.55%
Income Tax-1K-90K-269K-252K358K347K360K328K304K321K-71K242K00-100K
Effective Tax Rate %0.01%0.15%0.18%0.08%-0.12%-0.12%-0.19%-0.43%-0.35%-0.26%0.11%-0.28%0%0%0.31%
Net Income34.88M183.45M-47.58M-284.23M-293.65M-290.02M-189.29M-76.97M-86.42M-126.2M-61.68M-85.78M-59.5M-14.94M-32.57M
Net Margin %657.67%2848.63%-160.63%-607.29%-208.66%-123.25%-107.36%-30%-40.58%-100.43%-34.35%-47.44%-43.24%-14.63%-49.4%
Net Income Growth %-78.67%485.57%83.26%3.21%-1.25%-53.22%-145.93%10.94%31.52%-104.61%--44.16%-298.21%54.12%-
Net Income (Continuing)-17.61M-58.2M-153.1M-322.97M-293.65M-290.02M-189.29M-76.97M-86.42M-120.88M-61.68M-85.78M-59.5M-14.94M-32.57M
Discontinued Operations1000K241.66M105.52M38.74M00000000000
Minority Interest21.48M34.51M41.97M41.97M19.97M19.97M19.27M19.27M19.27M19.27M19.27M19.27M19.27M27.88M27.7M
EPS (Diluted)8.6145.37-11.89-73.03-78.45-78.51-2.11-0.89-1.03-1.73-0.98-1.42-1.04-0.32-2.47
EPS Growth %1557.69%481.58%83.72%6.91%0.08%-3620.85%-137.08%13.59%40.46%-76.53%--36.54%-225%87.04%-
EPS (Basic)-45.37-11.89-73.03-78.45-78.51-2.11-0.89-1.03-1.73-0.98-1.42-1.04-0.32-2.47
Diluted Shares Outstanding4.05M4.04M4M3.89M3.74M3.69M3.59M3.47M3.36M2.92M2.51M60.34M57.43M47.27M13.17M
Basic Shares Outstanding4.05M4.04M4M3.89M3.74M3.69M3.59M3.47M3.36M2.92M2.51M60.34M57.43M47.27M13.17M
Dividend Payout Ratio---------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Volatile quarterly revenue base

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Base Too Erratic for Trend Read

Based on the reported quarterly figures, KYNB's revenue swung from $46.3M in 2024Q3 to roughly $1.8M in 2026Q3, making any sustained growth trajectory difficult to establish from this income statement.

The sharp decline from the 2024 quarters to a sub-$4M run-rate suggests the prior revenue was either non-recurring or tied to a discrete event rather than a repeatable commercial base. Quarter-over-quarter growth readings swing between triple-digit gains and steep contractions, which points to lumpy recognition rather than durable demand. Investors should monitor whether the recent $1.3M to $3.7M band stabilizes before attributing any growth durability to the business.

Gross Margin Unanchored by Revenue Scale

As reported in the income statement, KYNB's gross margin has ranged from negative 31.6% to 136.3% across the periods shown, reflecting cost-of-revenue figures that move independently of a stable revenue base.

Gross margin readings this volatile are better interpreted as a product of small and irregular revenue denominators than as evidence of pricing power or structural cost advantage. Peers such as AKBA and PTCT report gross margins above 80%, a benchmark that KYNB has not consistently approached on a reported basis. Until revenue and cost of revenue move in a more predictable relationship, the margin profile warrants further investigation rather than a durable conclusion.

Operating Losses Persist Despite Cost Control

Based on reported figures, KYNB's operating margin remained negative in most periods, with R&D and SG&A consistently absorbing more than the gross profit generated, leaving operating income deeply negative.

The inability of gross profit to cover R&D and SG&A indicates that the cost base is not yet scaling against the revenue line, which is the opposite of positive operating leverage. Operating losses near $13.8M to $17.6M across recent quarters suggest the company remains in a investment-heavy phase. This raises the question of how long current spending can continue without a meaningful step-up in recognized revenue.

Net Income Dominated by Non-Operating Swings

According to the reported income statement, KYNB's net income diverges sharply from operating results, with $148.5M and $37.9M profits appearing in periods where operating income was negative, suggesting non-operating items drove the reported bottom line.

Net income swinging from a $148.5M gain in 2025Q3 to a $15.2M loss in 2026Q1 while operating losses stayed in a similar range points to large non-operating or one-time items. Reported EPS therefore carries limited information about underlying operating performance. Analysts should treat headline net income as unreliable for valuation until the drivers of these discrete gains are identified.

Bear Case Centers on Unsustained Revenue

The strongest challenge to KYNB's income statement is that the recent revenue recovery, from $1.3M to $3.7M, may not persist, and the company's reported losses could widen if revenue reverts toward the lower end of its range.

Short-seller scrutiny would likely focus on the gap between the 2024 revenue peak and the current run-rate, questioning whether the earlier figures reflected non-recurring activity. With operating losses consistently exceeding $5M per quarter, a return to sub-$2M revenue would leave the cost base poorly covered. Based on reported figures, the absence of a clearly repeatable revenue stream is the central vulnerability in this analysis.

KYNB — Frequently Asked Questions

Quick answers to the most common questions about buying KYNB stock.

What was Kyntra Bio, Inc.'s (KYNB) revenue in 2025?

For fiscal year 2025, Kyntra Bio, Inc. (KYNB) reported total revenue of $6.4M. This represents a 90.2% decline compared to $65.9M in 2012.

Is Kyntra Bio, Inc. (KYNB) profitable?

Kyntra Bio, Inc. (KYNB) is profitable, generating $183.5M in net income for the fiscal year ending 2025 with a net profit margin of 2848.6%.

What is Kyntra Bio, Inc.'s operating profit margin?

Kyntra Bio, Inc. (KYNB) reported an operating income of $-45.9M, resulting in an operating profit margin of -712.7%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Kyntra Bio, Inc.'s gross profit and gross margin?

Kyntra Bio, Inc. (KYNB) generated $5.9M in gross profit for the year, representing a gross profit margin of 91.4%. This demonstrates the company's core pricing power and production efficiency.